Star Therapeutics Stock

www.star-therapeutics.com/Healthcare / BioTech & PharmaFounded: 2018

Star Therapeutics, founded in 2018, is a biotechnology company that aims to look for gaps that exist in the fields of hematology and immunology. The goal is to create life-changing antibody therapies for people who lack options for diseases that do not currently have viable treatments. Star Therapeutics looks for ways to apply the treatments to a variety of diseases and also manages a portfolio of companies. Star Therapeutics is headquartered in San Francisco, California.

Register for Details

For more details on financing and valuation for Star Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Star Therapeutics.

Register Today

Team

Management Team

Kathy Dong
Chief Operating Officer
Sandip Panicker Ph.D
Chief Scientific Officer
Jeremy Boucher
Vice President & Head of Finance
Adam Rosenthal Ph.D
Founder, Chief Executive Officer, & President
Gary Patou MD
Chief Medical Officer

Board Members

Carl Gordon Ph.D
OrbiMed
Nancy Stagliano Ph.D
New Leaf Venture
Vijay Lathi
New Leaf Venture

Other companies like Star Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Investors shower Star Therapeutics with $90M for constellation of biotechs, antibody therapies
Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven existing investors. The new funds nearly double the $100 million Star had already raised since its founding in late 2018.
Updated on: Oct 3, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.